High Growth But Risks To Outlook

BMI View: Our view that Ukraine's pharmaceutical market will continue to see strong-double-digit growth into 2011 have now been confirmed. Supported by a return to economic growth, we maintain our view that the Ukraine is a highly rewarding but ultimately risk prone pharmaceutical market. BMI continues to be concerned that moves by the government to reduce the country's dependence on imported pharmaceuticals could be damaging for multinational companies, with the methods described externally as a 'highly protectionist course'.[1] We also believe this could have a negative effect on the country's investment climate.

To read the full article, please choose one of the following options: